Detalhe da pesquisa
1.
Insights into Praziquantel Metabolism and Potential Enantiomeric Cytochrome P450-Mediated Drug-Drug Interaction.
Drug Metab Dispos
; 48(6): 481-490, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32193358
2.
Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale.
J Pharmacokinet Pharmacodyn
; 45(5): 747-762, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30218416
3.
Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.
Drug Metab Dispos
; 44(10): 1550-61, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27493152
4.
Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients.
CPT Pharmacometrics Syst Pharmacol
; 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38807307
5.
Development and application of a PBPK modeling strategy to support antimalarial drug development.
CPT Pharmacometrics Syst Pharmacol
; 12(9): 1335-1346, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587640
6.
Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4.
Drug Metab Dispos
; 40(9): 1658-67, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22621802
7.
Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency.
Eur J Pharm Sci
; 165: 105913, 2021 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34146682
8.
IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.
Xenobiotica
; 40(5): 331-43, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20230210
9.
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
Clin Pharmacol Ther
; 107(5): 1082-1115, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628859
10.
The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall.
Eur J Pharm Sci
; 131: 195-207, 2019 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30776469
11.
Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.
Curr Drug Metab
; 8(7): 685-93, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17979656
12.
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.
J Clin Pharmacol
; 56 Suppl 7: S132-42, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27385171
13.
Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties.
ACS Med Chem Lett
; 4(11): 1037-41, 2013 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900603
14.
Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition.
Drug Metab Dispos
; 34(1): 166-75, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16221752